Meeting
2021 ASCO Quality Care Symposium
Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study.
Authors
Lawson Eng
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Melanie Lynn Powis, Geoffrey Liu, Jeffrey M. Peppercorn, Philippe L. Bedard, Monika K. Krzyzanowska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 303)
DOI
10.1200/JCO.2020.39.28_suppl.303
Abstract #
303
Poster Bd #
Online Only
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Quality Care Symposium
The Association of Antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on early emergency room and hospitalization utilization: A population-based study.
First Author: Lawson Eng
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Annual Meeting
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
First Author: Heather L. McArthur